-
@ 2e8970de:63345c7a
2025-05-31 19:51:28Enfortumab Vedotin and Pembrolizumab doubled survival rates, with fewer serious side effects in advanced bladder cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa2312117
https://stacker.news/items/993799